(Q35048211)

English

Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Matthew R Smith

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Richard Cook

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Ker-Ai Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Joel B Nelson

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

16 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

117

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

2077-2085

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

The critical role of the bone microenvironment in cancer metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

Markers of bone metabolism in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

Androgen deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

Markers of bone turnover in prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

Markers of bone turnover in bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3116053

8 July 2018

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25762

21 January 2018

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25762

21 January 2018

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25762

21 January 2018

Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25762

21 January 2018

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25762

21 January 2018

Obesity and prostate cancer: a growing problem

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25762

21 January 2018

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21523719

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.25762

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35048211&oldid=2087540726"